TAO Synergies (TAOX) Cash & Equivalents (2019 - 2026)
TAO Synergies' (TAOX) quarterly Cash & Equivalents came in at $2.4 million in Q2 2026, down 83.33% on a YoY basis from $14.4 million in Q2 2025, and down 34.17% quarter-over-quarter from $3.6 million in Q1 2026.
Analysis
TAO Synergies (TAOX) Cash & Equivalents (2019 - 2026) Analysis & Trends
TAO Synergies (TAOX) has reported Cash & Equivalents for 8 consecutive years, with $2.4 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Cash & Equivalents fell 83.33% year-over-year to $2.4 million; the trailing twelve-month figure through Jun 2026 stood at $2.4 million (down 83.33% YoY), and the FY2025 full-year result was $5.5 million, down 68.94% from the prior year.
- Cash & Equivalents retreated to $2.4 million in Q2 2026 per TAOX's latest filing, from $3.6 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $37.5 million in Q4 2022 and bottomed at $2.4 million in Q2 2026.
- Historically, Cash & Equivalents has averaged $22.5 million across 5 years, with a median of $26.3 million in 2024.
- The sharpest annual moves came in 2022 and 2026: Cash & Equivalents surged 110.8% in 2022, then plunged 83.33% in 2026.
- Over 5 years, Cash & Equivalents stood at $37.5 million in 2022, then decreased by 23.47% to $28.7 million in 2023, then tumbled by 38.33% to $17.7 million in 2024, then sank by 68.94% to $5.5 million in 2025, then plunged by 56.35% to $2.4 million in 2026.
- According to Business Quant data, Cash & Equivalents over the past three periods registered $2.4 million, $3.6 million, and $5.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.50 Bn | 197.51 Bn | 7.24 Bn | 13.99 Bn |
| 2 | Gilead Sciences | 181.29 Bn | 178.11 Bn | 6.22 Bn | 3.18 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 6.14 Bn |
| 4 | Regeneron Pharmaceuticals | 82.55 Bn | 74.56 Bn | 3.93 Bn | 2.46 Bn |
| 5 | Argenx Se | 61.65 Bn | 56.47 Bn | 1.37 Bn | 3.58 Bn |
| 6 | Moderna | 54.65 Bn | 49.52 Bn | 52.00 Mn | 1.72 Bn |
| 7 | Alnylam Pharmaceuticals | 34.18 Bn | 30.87 Bn | 992.69 Mn | 1.71 Bn |
| 8 | Biogen | 31.36 Bn | 30.07 Bn | 1.96 Bn | 1.29 Bn |
| 9 | Roivant Sciences | 30.01 Bn | 30.01 Bn | 1.16 Mn | 1.25 Bn |
| 10 | TAO Synergies | 30.79 Mn | 30.79 Mn | - | 2.40 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.40 Mn |
| Mar 31, 2026 | 3.65 Mn |
| Dec 31, 2025 | 5.50 Mn |
| Jun 30, 2025 | 14.40 Mn |
| Mar 31, 2025 | 14.83 Mn |
| Dec 31, 2024 | 17.70 Mn |
| Sep 30, 2024 | 19.63 Mn |
| Jun 30, 2024 | 25.00 Mn |
| Mar 31, 2024 | 26.33 Mn |
| Dec 31, 2023 | 28.70 Mn |
| Sep 30, 2023 | 31.73 Mn |
| Jun 30, 2023 | 32.90 Mn |
| Mar 31, 2023 | 35.80 Mn |
| Dec 31, 2022 | 37.50 Mn |
| Sep 30, 2022 | 26.33 Mn |
| Jun 30, 2022 | 28.80 Mn |
| Mar 31, 2022 | 31.30 Mn |
| Dec 31, 2021 | 34.21 Mn |
| Sep 30, 2021 | 31.30 Mn |
| Jun 30, 2021 | 31.70 Mn |